Abstract:Background Mortality is one of the most fundamental metrics of population health. The role of nutrition in reducing mortality is of great public health interest. High levels of homocysteine (HHcy, in part, due to low folate intake) are known to increase the risk of cardiovascular diseases. However, data are limited on the longitudinal association of HHcy levels with all‐cause mortality in low folate regions such as China. Objective In a population with relatively low folate intake and high rate of HHcy, we aimed to test the hypothesis that HHcy is associated with increased mortality and folic acid therapy can reduce the risk of all‐cause mortality associated with HHcy. We also examined whether the effect may be affected by individual MTHFR (a key enzyme involved in Hcy metabolism) gene C677T polymorphism. Methods We analyzed the data of 20,702 hypertensive adults (age: 59.6 ± 7.5 years) enrolled in the China Stroke Primary Prevention Trial (CSPPT), with measurements for individual baseline serum total Hcy (tHcy) levels and MTHFR C677T genotypes. These participants were randomized to receive 5‐year, double‐blind daily treatment with 10mg enalapril and 0.8mg folic acid (n=10,348) or 10mg enalapril alone (n=10,354). Kaplan‐Meier survival analysis and Cox proportionate hazard model were used to estimate the effect of tHcy levels on all‐cause mortality and to test effect modification by folic acid intervention and MTHFR C677T genotype. Results There were 622 (3%) all‐cause deaths during a mean treatment period of 4.5 years. There was a dose‐response relationship between tHcy quartiles and all‐cause mortality (P for trend<0.001) after adjusting for pertinent covariables. This relationship was stronger among participants with CC or CT genotypes than among those with TT genotype. Compared to the enalapril alone group, enalapril plus folic acid therapy further lowered the risk of all‐cause mortality associated with increased tHcy levels. The risk reduction was more pronounced in participants with CC or CT genotypes. Conclusions In this large‐scale study of population residing in a low folate region, we found that baseline tHcy levels were associated with all‐cause mortality in a dose‐response fashion; and folic acid therapy can lower the all‐cause mortality risk associated with HHcy. Our data suggest that tHcy and MTHFR genotypes may serve as biomarkers for risk stratification and folic acid therapy may offer a simple, inexpensive and safe intervention strategy to reduce mortality among population characterized by low folate intake and high rate of HHcy.

[Effect of Low-Dose Folate Treatment on Plasma Homocystyeine and Chemokine Levels in Patients with Hyperhomocysteinemia].

Effect of Homocysteine on Expression of Interleukin-8 in THP-1 Macrophages

Folic Acid Reverses Hyper-Responsiveness of LPS-induced Chemokine Secretion from Monocytes in Patients with Hyperhomocysteinemia

Folate in the United States Population and Its Association with Congestive Heart Failure

Association of Serum Folate Level with Severity of White Matter Hyperintensity and Presence of Cerebral Microbleeds

Effect of Long-Term Low-Dose Folic Acid Supplementation on Degree of Total Homocysteine-Lowering: Major Effect Modifiers

Treatment of Hyperhomocysteinemia with Folic Acid: Effects on Homocysteine Levels, Coagulation Status, and Oxidative Stress Markers

[Folic Acid Attenuates Homocysteine Induced Human Monocytes Chemokine Secretion Via Reducing NADPH Oxidase Activity].

The efficacy of folic acid on improving endothelial cell function in the treatment of patients with homocysteine:A Me-ta-analysis

MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering: Prospect for Precision Folic Acid Treatment.

Effect of Folic Acid on Endothelial Function and Plasma Homocysteine in Hypertensive Patients

MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults

A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia

<i>MTHFR</i> Gene and Serum Folate Interaction on Serum Homocysteine Lowering

Impact of Folic-Acid Intervention and Mthfrc677t Gene Polymorphism on All-Cause Mortality Associated with Elevated Serum Homocysteine Levels in Chinese Adults with Hypertension

Efficacy of Folic Acid Supplementation on Endothelial Function and Plasma Homocysteine Concentration in Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials

The Intervention Effect of Probucol Combined with Folic Acid and Vitamin B12 on Hyperhomocysteinemia in Rats

The Roles of Aerobic Exercise and Folate Supplementation in Hyperhomocysteinemia-Accelerated Atherosclerosis.

The Effects of High-Dose Folic Acid on Vascular Endothelial Function in Patients with Coronary Artery Disease and Undergone Interventional Therapy

[The Effect of Baseline Homocysteine Level on the Efficacy of Enalapril Maleate and Folic Acid Tablet in Lowering Blood Pressure and Plasma Homocysteine].

Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?